Global Combined Hormonal Contraceptive Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Combined Hormonal Contraceptive Market Research Report 2024
Combined hormonal contraceptive basically made by a combination of an estrogen and a progestogen which are primarily used to prevent unwanted pregnancies. Combined hormonal contraceptives are one of the effective contraceptives in modern medicine. Since late 1950s variety of innovation has been developed to improve the efficacy and safety of combined hormonal contraceptive. The trends have been shifted towards less androgenic progestogens and lower doses of estrogen and progestogen. Changing in drug doses and modification in drug component with the incorporation of new technologies that can reduce the risk factor and the continuing development of novel delivery systems that can be helpful to fulfill unmet needs of the market. The other health benefits of combined hormonal contraceptives include they reduce the risk of iron deficiency anemia, endometriosis, used in treating acne vulgaris, irregular menstrual flow, and polycystic ovarian syndrome. The mechanism of combined hormonal contraceptive is inhibition of follicle stimulating hormone and luteinizing hormone. Ethinylestradiol is the most common estrogen used in combined hormonal contraceptives, whereas other hormones are also used. The combined hormonal contraceptive products are available in various forms whereas pills have the maximum share in the combined hormonal contraceptive market. According to the Association of Women Health, around 100 million women use combined hormonal contraceptives throughout the world.
According to Mr Accuracy reports’s new survey, global Combined Hormonal Contraceptive market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Combined Hormonal Contraceptive market research.
The growth of the combined hormonal contraceptive market is driven by growing predominance and more productive medications with emerging interest in quick substitutes. Reduction in the cost of hospitalization and high efficacy can be the prime driving factors for the growth of the combined hormonal contraceptive market over the forecast period. In emerging countries, the adoption of combined hormonal contraceptives has increased, along with increasing health consciousness and awareness. Growing menstruating population worldwide and various initiatives taken by the governments, such as birth control and women health awareness programs, are factors expected to increase the usage of combined hormonal contraceptive products globally. Strategic collaborations and acquisitions among manufacturers are also expected to boost the growth of the combined hormonal contraceptive market. However, side effects related to the combined hormonal contraceptive products can hamper the growth of the combined hormonal contraceptive market.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Combined Hormonal Contraceptive market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Teva Pharmaceutical Industries
Bayer HealthCare Pharmaceuticals
Actavis
Pfizer
Johnson & Johnson
GlaxoSmithKline
Watson Pharma
Cipla
Novartis International
Segment by Type
Pills
Patch
Ring
Hospital Pharmacies
Retail Pharmacies
E-commerce
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Combined Hormonal Contraceptive report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Combined Hormonal Contraceptive market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Combined Hormonal Contraceptive market research.
The growth of the combined hormonal contraceptive market is driven by growing predominance and more productive medications with emerging interest in quick substitutes. Reduction in the cost of hospitalization and high efficacy can be the prime driving factors for the growth of the combined hormonal contraceptive market over the forecast period. In emerging countries, the adoption of combined hormonal contraceptives has increased, along with increasing health consciousness and awareness. Growing menstruating population worldwide and various initiatives taken by the governments, such as birth control and women health awareness programs, are factors expected to increase the usage of combined hormonal contraceptive products globally. Strategic collaborations and acquisitions among manufacturers are also expected to boost the growth of the combined hormonal contraceptive market. However, side effects related to the combined hormonal contraceptive products can hamper the growth of the combined hormonal contraceptive market.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Combined Hormonal Contraceptive market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Teva Pharmaceutical Industries
Bayer HealthCare Pharmaceuticals
Actavis
Pfizer
Johnson & Johnson
GlaxoSmithKline
Watson Pharma
Cipla
Novartis International
Segment by Type
Pills
Patch
Ring
Segment by Application
Hospital Pharmacies
Retail Pharmacies
E-commerce
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Combined Hormonal Contraceptive report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices